Research Use Only. Reference materials for laboratory research — not for human or veterinary use.
Home / Learn / Tirzepatide
GLP-1 / GIP receptor research · 5 articles

Tirzepatide

Tirzepatide (dual GIP/GLP-1 receptor agonist peptide; LY3298176) · 5 min read

Tirzepatide (LY3298176) is a synthetic 39-amino-acid linear peptide engineered as a single-molecule dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Its sequence is derived from the native GIP backbone and incorporates two 2-aminoisobutyric acid (Aib) substitutions, a C-terminal amide, and a C20 fatty-diacid moiety attached to the Lys20 side chain through a γ-glutamate / di-AEEA linker. It is offered strictly as a characterized reference material for in-vitro and analytical research. For Research Use Only — not for human or veterinary use.

Molecular identity

A 39-residue linear peptide with the molecular formula C₂₂₅H₃₄₈N₄₈O₆₈ and a monoisotopic/average molecular weight of approximately 4813.5 g/mol (CAS 2023788-19-2; PubChem CID 156588324). The sequence carries 2-aminoisobutyric acid (Aib) at positions 2 and 13 and a C-terminal amide.

Structural features

The Lys20 side chain is conjugated to a 1,20-eicosanedioic (C20) fatty diacid through a glutamic-acid spacer and two (2-(2-aminoethoxy)ethoxy)acetic acid (AEEA) units. This lipidation is discussed in the literature as the basis for albumin association, while the Aib substitutions are associated with resistance to dipeptidyl-peptidase cleavage in characterization studies.

Research context

In published in-vitro work, Tirzepatide is examined as a tool for probing simultaneous engagement of two incretin receptors (GIPR and GLP-1R) and the associated G-protein-coupled signaling, including comparative cAMP-response and receptor-binding assays relative to native incretins and single-target agonists.

Handling as a reference material

Supplied as a lyophilized powder at ≥98% (HPLC) purity for laboratory analytical and receptor-assay applications. Identity and purity are appropriate for use as an analytical reference standard. For Research Use Only; not intended for any in-vivo, diagnostic, or therapeutic application.

Documented in every box

Every Tirzepatide order includes a sealed, lot-controlled vial, the completed lot documentation, and a handling & storage card. Product-specific handling follows the supplied documentation and institutional SOPs.

Evidence limits and research safety

Research findings can differ by model, assay, purity, formulation, and study design. Published cell, biochemical, and pre-clinical observations do not establish human or veterinary safety, efficacy, dosing, or suitability. Researchers should review the applicable SDS, institutional safety procedures, waste requirements, and lot-specific documentation before handling any reference material.

Related research

Retatrutide · Semaglutide · AOD9604

Credible sources

Research context only. This article summarizes published in-vitro and pre-clinical research for scientific context. It is not a claim of efficacy or safety and does not constitute medical, usage, or dosing guidance. HELIX BioScience products are Research Use Only and not for human or veterinary use.

More on Tirzepatide

Methods note

Tirzepatide: structure and identity checks

Tirzepatide: structure and identity checks explains how a laboratory team can frame Tirzepatide as a characterized research reference for connecting a lipidated peptide record to an identity and mass-confirmation workflow. The emphasis is on reproducible preparation, analytical controls, and careful interpretation—not on therapeutic, diagnostic, or in-vivo use.

7 min read
Methods note

Tirzepatide: controls for a dual-receptor assay

Tirzepatide: controls for a dual-receptor assay explains how a laboratory team can frame Tirzepatide as a characterized research reference for separating assay-window behavior from the interpretation of a dual-target receptor experiment. The emphasis is on reproducible preparation, analytical controls, and careful interpretation—not on therapeutic, diagnostic, or in-vivo use.

7 min read
Methods note

Tirzepatide: method versioning for comparative runs

Tirzepatide: method versioning for comparative runs explains how a laboratory team can frame Tirzepatide as a characterized research reference for keeping a comparative run tied to the exact analytical method and reference record used. The emphasis is on reproducible preparation, analytical controls, and careful interpretation—not on therapeutic, diagnostic, or in-vivo use.

7 min read
Methods note

Tirzepatide: carryover and injection-order review

Tirzepatide: carryover and injection-order review explains how a laboratory team can frame Tirzepatide as a characterized research reference for checking whether injection order or carryover could distort a modified-peptide comparison. The emphasis is on reproducible preparation, analytical controls, and careful interpretation—not on therapeutic, diagnostic, or in-vivo use.

7 min read